These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
481 related articles for article (PubMed ID: 24508578)
21. Neural targets in the study and treatment of social cognition in autism spectrum disorder. Vahabzadeh A; Landino SM; Finger BC; Carlezon WA; McDougle CJ Handb Exp Pharmacol; 2015; 228():309-34. PubMed ID: 25977088 [TBL] [Abstract][Full Text] [Related]
22. Potential for oxytocin use in children and adolescents with mental illness. Netherton E; Schatte D Hum Psychopharmacol; 2011; 26(4-5):271-81. PubMed ID: 21751251 [TBL] [Abstract][Full Text] [Related]
23. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Yatawara CJ; Einfeld SL; Hickie IB; Davenport TA; Guastella AJ Mol Psychiatry; 2016 Sep; 21(9):1225-31. PubMed ID: 26503762 [TBL] [Abstract][Full Text] [Related]
24. A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research. DeMayo MM; Song YJC; Hickie IB; Guastella AJ Paediatr Drugs; 2017 Oct; 19(5):391-410. PubMed ID: 28721467 [TBL] [Abstract][Full Text] [Related]
25. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Yamasue H; Okada T; Munesue T; Kuroda M; Fujioka T; Uno Y; Matsumoto K; Kuwabara H; Mori D; Okamoto Y; Yoshimura Y; Kawakubo Y; Arioka Y; Kojima M; Yuhi T; Owada K; Yassin W; Kushima I; Benner S; Ogawa N; Eriguchi Y; Kawano N; Uemura Y; Yamamoto M; Kano Y; Kasai K; Higashida H; Ozaki N; Kosaka H Mol Psychiatry; 2020 Aug; 25(8):1849-1858. PubMed ID: 29955161 [TBL] [Abstract][Full Text] [Related]
26. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Finger EC; MacKinley J; Blair M; Oliver LD; Jesso S; Tartaglia MC; Borrie M; Wells J; Dziobek I; Pasternak S; Mitchell DG; Rankin K; Kertesz A; Boxer A Neurology; 2015 Jan; 84(2):174-81. PubMed ID: 25503617 [TBL] [Abstract][Full Text] [Related]
27. Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial. Kosaka H; Okamoto Y; Munesue T; Yamasue H; Inohara K; Fujioka T; Anme T; Orisaka M; Ishitobi M; Jung M; Fujisawa TX; Tanaka S; Arai S; Asano M; Saito DN; Sadato N; Tomoda A; Omori M; Sato M; Okazawa H; Higashida H; Wada Y Transl Psychiatry; 2016 Aug; 6(8):e872. PubMed ID: 27552585 [TBL] [Abstract][Full Text] [Related]
28. Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B). Spanos M; Chandrasekhar T; Kim SJ; Hamer RM; King BH; McDougle CJ; Sanders KB; Gregory SG; Kolevzon A; Veenstra-VanderWeele J; Sikich L Contemp Clin Trials; 2020 Nov; 98():106103. PubMed ID: 32777383 [TBL] [Abstract][Full Text] [Related]
29. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Watanabe T; Kuroda M; Kuwabara H; Aoki Y; Iwashiro N; Tatsunobu N; Takao H; Nippashi Y; Kawakubo Y; Kunimatsu A; Kasai K; Yamasue H Brain; 2015 Nov; 138(Pt 11):3400-12. PubMed ID: 26336909 [TBL] [Abstract][Full Text] [Related]
30. Longitudinal follow-up of autism spectrum features and sensory behaviors in Angelman syndrome by deletion class. Peters SU; Horowitz L; Barbieri-Welge R; Taylor JL; Hundley RJ J Child Psychol Psychiatry; 2012 Feb; 53(2):152-9. PubMed ID: 21831244 [TBL] [Abstract][Full Text] [Related]
31. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Davis MC; Lee J; Horan WP; Clarke AD; McGee MR; Green MF; Marder SR Schizophr Res; 2013 Jul; 147(2-3):393-7. PubMed ID: 23676253 [TBL] [Abstract][Full Text] [Related]
32. Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms. Kato Y; Kuwabara H; Okada T; Munesue T; Benner S; Kuroda M; Kojima M; Yassin W; Eriguchi Y; Kameno Y; Murayama C; Nishimura T; Tsuchiya K; Kasai K; Ozaki N; Kosaka H; Yamasue H Mol Autism; 2021 Feb; 12(1):15. PubMed ID: 33622389 [TBL] [Abstract][Full Text] [Related]
33. Neural modulation of social reinforcement learning by intranasal oxytocin in male adults with high-functioning autism spectrum disorder: a randomized trial. Kruppa JA; Gossen A; Oberwelland Weiß E; Kohls G; Großheinrich N; Cholemkery H; Freitag CM; Karges W; Wölfle E; Sinzig J; Fink GR; Herpertz-Dahlmann B; Konrad K; Schulte-Rüther M Neuropsychopharmacology; 2019 Mar; 44(4):749-756. PubMed ID: 30390065 [TBL] [Abstract][Full Text] [Related]
36. Cochrane review: social skills groups for people aged 6 to 21 with autism spectrum disorders (ASD). Reichow B; Steiner AM; Volkmar F Evid Based Child Health; 2013 Mar; 8(2):266-315. PubMed ID: 23877884 [TBL] [Abstract][Full Text] [Related]
37. Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Bernaerts S; Boets B; Bosmans G; Steyaert J; Alaerts K Mol Autism; 2020; 11(1):6. PubMed ID: 31969977 [TBL] [Abstract][Full Text] [Related]
38. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Ji N; Findling RL Curr Opin Psychiatry; 2015 Mar; 28(2):91-101. PubMed ID: 25602248 [TBL] [Abstract][Full Text] [Related]
39. A single dose of oxytocin nasal spray improves higher-order social cognition in schizophrenia. Guastella AJ; Ward PB; Hickie IB; Shahrestani S; Hodge MA; Scott EM; Langdon R Schizophr Res; 2015 Nov; 168(3):628-33. PubMed ID: 26150070 [TBL] [Abstract][Full Text] [Related]
40. Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders. Francis SM; Sagar A; Levin-Decanini T; Liu W; Carter CS; Jacob S Brain Res; 2014 Sep; 1580():199-218. PubMed ID: 24462936 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]